Summary
73.35 0.35(0.48%)09/16/2024
Nasdaq Inc (NDAQ)
Nasdaq Inc (NDAQ)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.48 | 1.54 | 5.91 | 23.29 | 22.67 | 42.87 | 129.82 | 1,636.20 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 73.35 | |
| Open | 73.29 | |
| High | 73.69 | |
| Low | 73.03 | |
| Volume | 1,305,547 | |
| Change | 0.35 | |
| Change % | 0.48 | |
| Avg Volume (20 Days) | 1,539,499 | |
| Volume/Avg Volume (20 Days) Ratio | 0.85 | |
| 52 Week Range | 46.88 - 74.17 | |
| Price vs 52 Week High | -1.11% | |
| Price vs 52 Week Low | 56.46% | |
| Range | 0.81 | |
| Gap Up/Down | -0.26 | |
Fundamentals | ||
| Market Capitalization (Mln) | 41,956 | |
| EBIDTA | 2,262,000,128 | |
| PE Ratio | 32.4385 | |
| PEG Ratio | 1.9779 | |
| WallStreet Target Price | 65.33 | |
| Book Value | 18.7730 | |
| Earnings Per Share | 1.8700 | |
| EPS Estimate Current Quarter | 0.6500 | |
| EPS Estimate Next Quarter | 0.6800 | |
| EPS Estimate Current Year | 2.6700 | |
| EPS Estimate Next Year | 3.0200 | |
| Diluted EPS (TTM) | 1.8700 | |
| Revenues | ||
| Profit Marging | 0.1597 | |
| Operating Marging (TTM) | 0.2712 | |
| Return on asset (TTM) | 0.0454 | |
| Return on equity (TTM) | 0.1164 | |
| Revenue TTM | 6,205,000,192 | |
| Revenue per share TTM | 11.7900 | |
| Quarterly Revenue Growth (YOY) | 0.0920 | |
| Quarterly Earnings Growth (YOY) | -0.3440 | |
| Gross Profit (TTM) | 3,582,000,000 | |
| Dividends | ||
| Dividend Share | 0.8800 | |
| Dividend Yield | 0.0158 | |
| Valuations | ||
| Trailing PE | 32.4385 | |
| Forward PE | 22.7273 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 3.2748 | |
| Revenue Enterprise Value | 7.5281 | |
| EBITDA Enterprise Value | 22.8711 | |
| Shares | ||
| Shares Outstanding | 576,532,992 | |
| Shares Float | 442,800,086 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.01 | |
| Insider (%) | 10.73 | |
| Institutions (%) | 78.48 | |
09/16 12:01 EST - zacks.com
5 Stocks Fueling Nasdaq ETF's Best Week in 2024
The Nasdaq Composite Index has outperformed last week on looming rate cuts. We have highlighted five best-performing stocks of QQQ that led the way higher.
5 Stocks Fueling Nasdaq ETF's Best Week in 2024
The Nasdaq Composite Index has outperformed last week on looming rate cuts. We have highlighted five best-performing stocks of QQQ that led the way higher.
09/16 11:50 EST - fxempire.com
Nasdaq Index: Chip Stocks Slump, Intel Rises Amid Uncertainty in US Indices
Chip stocks slide as Fed rate cut looms. Intel shines with a $3.5B federal grant.
Nasdaq Index: Chip Stocks Slump, Intel Rises Amid Uncertainty in US Indices
Chip stocks slide as Fed rate cut looms. Intel shines with a $3.5B federal grant.
09/16 09:46 EST - prnewswire.com
Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm
STOCKHOLM , Sept. 16, 2024 /PRNewswire/ -- Nasdaq Stockholm has decided that Calliditas Therapeutics AB (publ) will be delisted from Nasdaq Stockholm.
Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm
STOCKHOLM , Sept. 16, 2024 /PRNewswire/ -- Nasdaq Stockholm has decided that Calliditas Therapeutics AB (publ) will be delisted from Nasdaq Stockholm.
09/16 09:00 EST - prnewswire.com
Intelligent Living Application Group Inc. Regains Compliance with Nasdaq's Minimum Bid Price Rule
HONG KONG, Sept. 16, 2024 /PRNewswire/ -- Intelligent Living Application Group Inc. (NASDAQ: ILAG) ("Intelligent Living" or the "Company"), a premium lockset manufacturer in Hong Kong, announced today that it has regained compliance with the $1 minimum bid price requirement under the continued listing requirements of the Nasdaq Stock Market LLC ("Nasdaq").
Intelligent Living Application Group Inc. Regains Compliance with Nasdaq's Minimum Bid Price Rule
HONG KONG, Sept. 16, 2024 /PRNewswire/ -- Intelligent Living Application Group Inc. (NASDAQ: ILAG) ("Intelligent Living" or the "Company"), a premium lockset manufacturer in Hong Kong, announced today that it has regained compliance with the $1 minimum bid price requirement under the continued listing requirements of the Nasdaq Stock Market LLC ("Nasdaq").
09/16 08:30 EST - globenewswire.com
Veea Inc. and Plum Acquisition Corp. I Announce Closing of Business Combination
The combined company will begin trading on the Nasdaq Capital Market under the ticker symbols “VEEA” for its common stock and “VEEAW” for its publicly traded warrants The combined company will begin trading on the Nasdaq Capital Market under the ticker symbols “VEEA” for its common stock and “VEEAW” for its publicly traded warrants
Veea Inc. and Plum Acquisition Corp. I Announce Closing of Business Combination
The combined company will begin trading on the Nasdaq Capital Market under the ticker symbols “VEEA” for its common stock and “VEEAW” for its publicly traded warrants The combined company will begin trading on the Nasdaq Capital Market under the ticker symbols “VEEA” for its common stock and “VEEAW” for its publicly traded warrants
09/16 07:30 EST - globenewswire.com
ECD Regains Compliance with Nasdaq Continued Listing Requirement
KISSIMMEE, Fla., Sept. 16, 2024 (GLOBE NEWSWIRE) -- ECD Automotive Design, Inc. (Nasdaq:ECDA) (“ECD” or the “Company”), an industry leader in delivering restored, modified and electrified Land Rover Defenders, Jaguars, and other classic and collectible automobiles announced today that it received a letter from The Nasdaq Stock Market ("Nasdaq") stating that Nasdaq has approved ECD's application to list its shares of common stock for trading on the Nasdaq Capital Market effective September 13, 2024.
ECD Regains Compliance with Nasdaq Continued Listing Requirement
KISSIMMEE, Fla., Sept. 16, 2024 (GLOBE NEWSWIRE) -- ECD Automotive Design, Inc. (Nasdaq:ECDA) (“ECD” or the “Company”), an industry leader in delivering restored, modified and electrified Land Rover Defenders, Jaguars, and other classic and collectible automobiles announced today that it received a letter from The Nasdaq Stock Market ("Nasdaq") stating that Nasdaq has approved ECD's application to list its shares of common stock for trading on the Nasdaq Capital Market effective September 13, 2024.
09/16 05:17 EST - fool.com
Should You Buy the 3 Highest-Paying Dividend Stocks in the Nasdaq?
High dividend yields often signal financial struggles rather than lucrative opportunities. The "dogs of the Dow" strategy may not work well with Nasdaq's top-yielding dividend stocks.
Should You Buy the 3 Highest-Paying Dividend Stocks in the Nasdaq?
High dividend yields often signal financial struggles rather than lucrative opportunities. The "dogs of the Dow" strategy may not work well with Nasdaq's top-yielding dividend stocks.
09/16 03:47 EST - benzinga.com
S&P 500, Nasdaq Record Best Week Of Year As Alphabet, Super Micro Surge: Fear & Greed Index Moves To 'Neutral' Zone
The CNN Money Fear and Greed index showed an improvement in the overall market sentiment, while the index moved to the “Neutral” zone on Friday.
S&P 500, Nasdaq Record Best Week Of Year As Alphabet, Super Micro Surge: Fear & Greed Index Moves To 'Neutral' Zone
The CNN Money Fear and Greed index showed an improvement in the overall market sentiment, while the index moved to the “Neutral” zone on Friday.
09/14 05:09 EST - seekingalpha.com
Leveraged Exposure To The Nasdaq 100 Via TQQQ: Is It Worth The Risk?
TQQQ offers triple the daily returns of the Nasdaq 100, suitable for short-term trading but risky for long-term holding due to volatility decay. Leveraged ETFs like TQQQ face high volatility and daily rebalancing effects, making them inappropriate for buy-and-hold investors. TQQQ's 0.88% expense ratio is fair for its speculative nature but adds to the long-term underperformance risk.
Leveraged Exposure To The Nasdaq 100 Via TQQQ: Is It Worth The Risk?
TQQQ offers triple the daily returns of the Nasdaq 100, suitable for short-term trading but risky for long-term holding due to volatility decay. Leveraged ETFs like TQQQ face high volatility and daily rebalancing effects, making them inappropriate for buy-and-hold investors. TQQQ's 0.88% expense ratio is fair for its speculative nature but adds to the long-term underperformance risk.
09/13 18:30 EST - accesswire.com
Moolec Received NASDAQ Bid Price Letter
LUXEMBOURG / ACCESSWIRE / September 13, 2024 / Moolec Science SA (NASDAQ:MLEC) ("The Company", "Moolec"), a science-based food ingredient company, announced today that it received a letter (the "Nasdaq Bid Price Letter") from Nasdaq notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company's ordinary shares has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). The Nasdaq Bid Price Letter has no immediate effect on the listing of the Company's common stock, and its common stock will continue to trade on The Nasdaq Capital Market under the symbol "MLEC".
Moolec Received NASDAQ Bid Price Letter
LUXEMBOURG / ACCESSWIRE / September 13, 2024 / Moolec Science SA (NASDAQ:MLEC) ("The Company", "Moolec"), a science-based food ingredient company, announced today that it received a letter (the "Nasdaq Bid Price Letter") from Nasdaq notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company's ordinary shares has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). The Nasdaq Bid Price Letter has no immediate effect on the listing of the Company's common stock, and its common stock will continue to trade on The Nasdaq Capital Market under the symbol "MLEC".
09/13 17:30 EST - fool.com
Nasdaq Correction: 1 No-Brainer Stock to Buy On This Dip
Alphabet is down 20% from highs set earlier this year. The narrative that the company is losing in AI is misguided.
Nasdaq Correction: 1 No-Brainer Stock to Buy On This Dip
Alphabet is down 20% from highs set earlier this year. The narrative that the company is losing in AI is misguided.
09/13 16:30 EST - globenewswire.com
NorthView Acquisition Corporation Announces Exception Granted by Nasdaq to Permit to The Company to Regain Compliance with Listing Rules
New York, NY, Sept. 13, 2024 (GLOBE NEWSWIRE) -- NorthView Acquisition Corporation. (Nasdaq: NVAC) (the “Company”) announced that it has received a notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) granting the Company an exception to regain compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the “SEC”). Pursuant to the terms of the exception, the Company must file its Quarterly Reports on Form 10-Q for the periods ending March 31, 2024 and June 30, 2024 on or prior to October 14, 2024. If the Company does not satisfy the terms of the exception, the Staff will provide written notification that the Company's securities will be delisted. At such time, the Company could appeal the Staff's determination to a Hearings Panel.
NorthView Acquisition Corporation Announces Exception Granted by Nasdaq to Permit to The Company to Regain Compliance with Listing Rules
New York, NY, Sept. 13, 2024 (GLOBE NEWSWIRE) -- NorthView Acquisition Corporation. (Nasdaq: NVAC) (the “Company”) announced that it has received a notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) granting the Company an exception to regain compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the “SEC”). Pursuant to the terms of the exception, the Company must file its Quarterly Reports on Form 10-Q for the periods ending March 31, 2024 and June 30, 2024 on or prior to October 14, 2024. If the Company does not satisfy the terms of the exception, the Staff will provide written notification that the Company's securities will be delisted. At such time, the Company could appeal the Staff's determination to a Hearings Panel.
09/13 16:30 EST - globenewswire.com
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to three new employees. Fulcrum granted stock options to purchase shares of the company's common stock pursuant to the company's 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employees entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to three new employees. Fulcrum granted stock options to purchase shares of the company's common stock pursuant to the company's 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employees entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).
09/13 12:36 EST - reuters.com
MBX Biosciences shares surge 44% in blockbuster Nasdaq debut
Shares of MBX Biosciences , which is developing therapies that target endocrine and metabolic disorders, including diabetes and obesity, rose nearly 44% in their Nasdaq debut on Friday, underscoring investors' focus on weight-loss drugs.
MBX Biosciences shares surge 44% in blockbuster Nasdaq debut
Shares of MBX Biosciences , which is developing therapies that target endocrine and metabolic disorders, including diabetes and obesity, rose nearly 44% in their Nasdaq debut on Friday, underscoring investors' focus on weight-loss drugs.
09/13 08:45 EST - globenewswire.com
Allarity Therapeutics Announces New CFO and Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- New CFO Brings Multiple Years of Experience from Biotech Companies - As Part of the New Hire, the Company Issues Inducement Grants
Allarity Therapeutics Announces New CFO and Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- New CFO Brings Multiple Years of Experience from Biotech Companies - As Part of the New Hire, the Company Issues Inducement Grants
09/13 08:00 EST - globenewswire.com
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option to purchase an aggregate of 3,500 shares of the Company's stock (the “Inducement Grant”) to a newly hired employee on September 10, 2024 (the “Grant Date”), in connection with the commencement of employment.
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option to purchase an aggregate of 3,500 shares of the Company's stock (the “Inducement Grant”) to a newly hired employee on September 10, 2024 (the “Grant Date”), in connection with the commencement of employment.
09/13 07:44 EST - fool.com
New Nasdaq-100 Dividend Payer: Is This the Perfect Dividend Growth Stock?
Alphabet began to pay a dividend this spring. The payout equates to a low yield now, but the tech giant has plenty of room to grow its dividend.
New Nasdaq-100 Dividend Payer: Is This the Perfect Dividend Growth Stock?
Alphabet began to pay a dividend this spring. The payout equates to a low yield now, but the tech giant has plenty of room to grow its dividend.
09/13 07:20 EST - fool.com
This Dividend Stock Is Outperforming the S&P 500, Nasdaq, and Dow Jones This Year -- Is It a Buy?
AT&T has been able to focus on its core telecom business after dropping its media ambitions. The telecom giant offers an ultra-high dividend yield while maintaining a good payout ratio.
This Dividend Stock Is Outperforming the S&P 500, Nasdaq, and Dow Jones This Year -- Is It a Buy?
AT&T has been able to focus on its core telecom business after dropping its media ambitions. The telecom giant offers an ultra-high dividend yield while maintaining a good payout ratio.
09/12 21:30 EST - accesswire.com
Tenon Medical, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
LOS GATOS, CA / ACCESSWIRE / September 12, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacroiliac joint (SI Joint) disorders, today announced the pricing of its "reasonable best efforts" public offering with a single health-care focused institutional investor for the purchase and sale of up to 1,222,850 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 1,222,850 shares of common stock at a combined offering price of $3.68 per share and accompanying warrant, priced at-the-market under Nasdaq rules (the "Offering"). The Company expects to receive aggregate gross proceeds of approximately $4.5 million, before deducting placement agent fees and other offering expenses, and assuming no exercise of the warrants.
Tenon Medical, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
LOS GATOS, CA / ACCESSWIRE / September 12, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacroiliac joint (SI Joint) disorders, today announced the pricing of its "reasonable best efforts" public offering with a single health-care focused institutional investor for the purchase and sale of up to 1,222,850 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 1,222,850 shares of common stock at a combined offering price of $3.68 per share and accompanying warrant, priced at-the-market under Nasdaq rules (the "Offering"). The Company expects to receive aggregate gross proceeds of approximately $4.5 million, before deducting placement agent fees and other offering expenses, and assuming no exercise of the warrants.
09/12 17:00 EST - globenewswire.com
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on September 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 33,500 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan (“2018 Plan”), but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4).
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on September 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 33,500 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan (“2018 Plan”), but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4).